IRADIMED CORP — fact timeline

IRADIMED CORP reported first quarter of 2026 results: revenue revenue of $22.0 million, net income net income of $5.8 million, EPS $0.45 per diluted share. Guidance reaffirmed.

“IRADIMED CORPORATION Reports First Quarter 2026 Financial Results Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance • Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025. • Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.”

IRADIMED CORP reported the three months ended March 31, 2024 results: revenue $17.6 million, net income $4.1 million, EPS $0.32 per diluted share. Guidance reaffirmed.

“IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share ● Reports record revenue of $17.6 million for the first quarter of 2024. ​ ● Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024. ​ ● Reports first quarter of 2024 operating”

IRADIMED CORP reported the fourth quarter and full year ended December 31, 2023 results: revenue $17.5 million for the fourth quarter and $65.6 million for the full year of 2023, net income $4.5 million, or $0.36 per diluted share, EPS $0.36. Guidance initiated.

“IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results ● Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023.”

IRADIMED CORP reported fourth quarter 2023 results: EPS $0.38 to $0.41. Guidance initiated.

“For the fourth quarter of 2023, the Company expects to report revenue of $16.9 million to $17.4 million, GAAP diluted earnings per share of $0.35 to $0.38, and non-GAAP diluted earnings per share of $0.38 to $0.41.”

IRADIMED CORP reported full-year 2023 results: EPS $1.48 to $1.51. Guidance raised.

“For the full-year 2023 financial guidance, the Company now expects to report revenue of $65.0 million to $65.5 million, GAAP diluted earnings per share of $1.34 to $1.37, and non-GAAP diluted earnings per share of $1.48 to $1.51.”

IRADIMED CORP reported nine months ended September 30, 2023 results: net income $14.0 million, EPS $1.1.

“For the nine months ended September 30, 2023, the Company reported revenue of $48.1 million compared to $38.4 million for the same period of 2022. Net income was $12.7 million, or $0.99 per diluted share, compared to $9.2 million, or $0.72 per diluted share for the same period of 2022.”

IRADIMED CORP reported third quarter ended September 30, 2023 results: net income $5.5 million, EPS $0.43.

“For the third quarter ended September 30, 2023, the Company reported over 23% year-over-year revenue growth to $16.5 million compared to $13.4 million for the third quarter of 2022. Net income was $5.1 million, or $0.40 per diluted share, compared to $3.4 million, or $0.27 per diluted share for the third quarter of 2022.”

IRADIMED CORP reported second quarter ended June 30, 2023 results: revenue $16.1 million, net income $4.2 million, EPS $0.33 per diluted share. Guidance raised.

“For the second quarter ended June 30, 2023, the Company reported over 25% year-over-year revenue growth to $16.1 million compared to $12.7 million for the second quarter of 2022. Net income was $4.2 million, or $0.33 per diluted share, compared to $3.2 million, or $0.26 per diluted share for the second quarter of 2022.”

IRADIMED CORP shareholders approved Amendment to our Restated Certificate of Incorporation to limit the liability of certain officers of the Company at the 2023-06-15 meeting.

“Stockholders approved an amendment to our Restated Certificate of Incorporation to limit the liability of certain officers of the Company.”

IRADIMED CORP shareholders approved Approval of the Iradimed Corporation 2023 Equity Incentive Plan at the 2023-06-15 meeting.

“Stockholders approved the Iradimed Corporation 2023 Equity Incentive Plan.”

IRADIMED CORP shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2023-06-15 meeting.

“Stockholders voted, on an advisory basis, on the frequency of future advisory votes on executive compensation.”

IRADIMED CORP shareholders approved Advisory resolution on the compensation of Iradimed's named executive officers at the 2023-06-15 meeting.

“Stockholders approved an advisory resolution on the compensation of Iradimed's named executive officers.”

IRADIMED CORP shareholders approved Ratification of the selection of RSM US LLP as Iradimed's independent registered public accounting firm to perform independent audit services for the fiscal year ending December 31, 2023 at the 2023-06-15 meeting.

“Stockholders ratified the selection of RSM US LLP as Iradimed's independent registered public accounting firm to perform independent audit services for the fiscal year ending December 31, 2023, as set forth below.”

IRADIMED CORP shareholders approved Election of Directors at the 2023-06-15 meeting.

“Stockholders elected each of Roger Susi, Monty Allen, Anthony Vuoto, Hilda Scharen-Guivel and James Hawkins to Iradimed's Board of Directors, each to hold office until a succeeding annual meeting of stockholders or until such director's successor shall have been duly elected and qualified (or, if earlier, such director's removal or resignation from our Board), as set forth below.”

IRADIMED CORP reported full-year 2023 results: revenue $62 million to $63.5 million, EPS $1.13 to $1.21. Guidance raised.

“The Company increased its full-year 2023 financial guidance and now expects to report revenue of $62 million to $63.5 million, GAAP diluted earnings per share of $1.13 to $1.21, and non-GAAP diluted earnings per share of $1.26 to $1.35.”

IRADIMED CORP reported the second quarter of 2023 results: revenue $15.6 million to $15.8 million, EPS $0.27 to $0.29. Guidance initiated.

“For the second quarter of 2023, the Company expects to report revenue of $15.6 million to $15.8 million, GAAP diluted earnings per share of $0.27 to $0.29, and non-GAAP diluted earnings per share of $0.30 to $0.32.”

IRADIMED CORP reported the first quarter ended March 31, 2023 results: revenue $15.5 million, net income $3.4 million, EPS $0.27 per diluted share.

“For the first quarter ended March 31, 2023, the Company reported over 25% year-over-year revenue growth to $15.5 million compared to $12.3 million for the first quarter of 2022. Net income was $3.4 million, or $0.27 per diluted share, compared to $2.5 million, or $0.20 per diluted share for the first quarter of 2022.”

IRADIMED CORP amended Reinstatement with O Property, Ltd. valued at $6,200,000 (effective 2023-02-02).

“On February 2, 2023, iRadimed Corporation (the “Company”) entered into a reinstatement and amendment (the “Reinstatement”) to the previously announced sale and purchase agreement with O Property, Ltd., a Florida limited partnership (the “Purchase Agreement”) dated as of November 1, 2022, pursuant to which the parties agreed to consummate a sale of real property located in Orange County, Florida. Pursuant to the terms of the Reinstatement, the parties consummated the sale of approximately 26.518 acres of land to the Company for a purchase price of $6,200,000.”

IRADIMED CORP reported first quarter of 2023 results: revenue $14.6 million to $14.9 million, EPS $0.23 to $0.25 per diluted share (GAAP). Guidance initiated.

“For the first quarter of 2023, the Company expects to report revenue of $14.6 million to $14.9 million, GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28.”

IRADIMED CORP reported full year 2023 results: revenue $61 million to $63 million, EPS $1.10 to $1.20 per diluted share (GAAP). Guidance initiated.

“For the full year 2023, the Company expects to report revenue of $61 million to $63 million, GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34.”

IRADIMED CORP reported the twelve months ended December 31, 2022 results: revenue $53.3 million, net income $12.8 million, EPS $1.02 per diluted share. Guidance initiated.

“For the twelve months ended December 31, 2022, the Company reported revenue of $53.3 million compared to $41.8 million for the same period in 2021. Net income was $12.8 million, or $1.02 per diluted share, compared to $9.3 million, or $0.74 per diluted share, for the same period in 2021.”

IRADIMED CORP reported the fourth quarter ended December 31, 2022 results: revenue $14.9 million, net income $3.7 million, EPS $0.29 per diluted share. Guidance initiated.

“For the fourth quarter ended December 31, 2022, the Company reported revenue of $14.9 million compared to $11.9 million for the fourth quarter of 2021. Net income was $3.7 million, or $0.29 per diluted share, compared to $3.9 million, or $0.31 per diluted share, for the fourth quarter of 2021.”

IRADIMED CORP reported the first quarter of 2023 results: revenue $14.6 million to $14.9 million, EPS GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28. Guidance initiated.

“For the first quarter of 2023, the Company expects to report revenue of $14.6 million to $14.9 million, GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28.”

IRADIMED CORP reported the full year 2023 results: revenue $61 million to $63 million, EPS GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34. Guidance initiated.

“For the full year 2023, the Company expects to report revenue of $61 million to $63 million, GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34.”

IRADIMED CORP reported the fourth quarter ended December 31, 2022 results: revenue $14.9 million.

“Fourth-quarter revenue is expected to be approximately $14.9 million”

IRADIMED CORP incurred debt of $7,300,000 with O Property, Ltd..

“in Orange County, Florida. Under the terms of the Purchase Agreement, O Property, Ltd. agreed to sell approximately 27.19 acres of land to the Company for a purchase price of $7,300,000. The foregoing description of the terms of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, a copy”

IRADIMED CORP entered into Purchase Agreement with O Property, Ltd. valued at $7,300,000 (effective 2022-11-01).

“On November 1, 2022, Iradimed Corporation (the “Company”) entered into a sale and purchase agreement with O Property, Ltd., a Florida limited partnership (the “Purchase Agreement”), pursuant to which the parties agreed to consummate a sale of real property located in Orange County, Florida. Under the terms of the Purchase Agreement, O Property, Ltd. agreed to sell approximately 27.19 acres of land to the Company for a purchase price of $7,300,000.”

IRADIMED CORP reported financial results for the third quarter ended September 30, 2022.

“On November 3, 2022, iRadimed Corporation issued a press release (the “Press Release”) announcing its financial results for the third quarter ended September 30, 2022.”

Hilda Scharen-Guivel was elected as Director at IRADIMED CORP.

“elected Ms. Hilda Scharen-Guivel as a Director, both effective October 4, 2022.”

John (Jack) Glenn was appointed as Chief Financial Officer at IRADIMED CORP.

“On May 26, 2022, iRadimed Corporation (the “Company”) issued a press release announcing the appointment of John (Jack) Glenn as Chief Financial Officer of the Company, effective on or before June 20, 2022.”

Matt Garner was appointed as interim Chief Financial Officer at IRADIMED CORP.

“has appointed Matt Garner, Controller, to serve as interim Chief Financial Officer, effective April 28, 2022.”

Chris Scott resigned as Chief Financial and Operating Officer at IRADIMED CORP.

“announcing the resignation of Chris Scott, Chief Financial and Operating Officer of iRadimed Corporation (the “Company”), effective May 27, 2022.”

Chris Scott was appointed as Chief Financial and Operating Officer at IRADIMED CORP.

“On July 8, 2021, Iradimed Corporation (the “Company”) appointed Chris Scott, 51, as its Chief Financial and Operating Officer effective immediately.”